Amicus Therapeutics Inc - ESG Rating & Company Profile powered by AI
If you work at Amicus Therapeutics Inc and you would like to use your Sustainability aseessment, please contact us. This page displays a zero-cost ESG assessment for Amicus Therapeutics Inc. This assessment of Amicus Therapeutics Inc was prepared by All Street Sevva using proprietary artificial intelligence.
Amicus Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.3; made up of an environmental score of 1.3, social score of 3.4 and governance score of 5.3.
3.3
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1234 | Quanterix Corp | 3.4 | Medium |
| 1234 | X4 Pharmaceuticals Inc | 3.4 | Medium |
| 1253 | Amicus Therapeutics Inc | 3.3 | Medium |
| 1253 | Calithera Biosciences Inc | 3.3 | Medium |
| 1253 | Cara Therapeutics Inc | 3.3 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Amicus Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Amicus Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Amicus Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Amicus Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Amicus Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Amicus Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Amicus Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Amicus Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Amicus Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Amicus Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Amicus Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Amicus Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Amicus Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Amicus Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Amicus Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Amicus Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Amicus Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Amicus Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.